Behandling med topotecan + cisplatin resulterede i en statistisk signifikant forlængelse af den samlede overlevelse i forhold til cisplatin- monoterapi efter justering for interimanalyser (Log- rank p = 0, 033).
Topotecan plus cisplatin had a statistically significant benefit in overall survival relative to cisplatin monotherapy after adjusting for interim analyses (Log-rank p =0.033).